grant
Advancing a novel synthetic lethal target by exploiting ribosomal stress in Ch9p21.3-deleted or MSI-H cancers
Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 1 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY20269p21.3AllelesAllelomorphsAssayAutoregulationBaker's YeastBindingBioassayBiological AssayBrewer's YeastCancer TreatmentCancersCell BodyCell Death InductionCell SurvivalCell ViabilityCellsChromosomal DeletionChromosome DeletionChromosomesClinical Drug DevelopmentClinical Drug Testing/DevelopmentClinical TrialsColorectal CancerComplexDNA HelicasesDNA Unwinding ProteinsDNA mutationDNA unwinding enzymeDataDeletion MutationDependenceDevelopmentDrug TargetingDysfunctionER stressEndometrial CancerEndometrial CarcinomaEndometrium CancerEndometrium CarcinomaEndoplasmic ReticulumErgastoplasmEsophageal CancerEsophagus CancerExhibitsFood and Drug AdministrationFunctional disorderGTP PhosphohydrolasesGTPasesGastric Body CancerGastric CancerGastric Cardia CancerGastric Fundus CancerGastric Pylorus CancerGeneHomologGenesGenetic ChangeGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic defectGenetic mutationGenomeGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGuanosine Triphosphate PhosphohydrolasesGuanosinetriphosphatasesHealth PlanningHomeostasisHomologHomologous GeneHomologueHumanImpairmentLinkMalignant CellMalignant Esophageal NeoplasmMalignant Esophageal TumorMalignant Gastric NeoplasmMalignant Gastric TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant Tumor of the EsophagusMalignant neoplasm of esophagusMalignant neoplasm of pancreasManuscriptsMembraneMessenger RNAMiceMice MammalsMicrosatellite InstabilityMicrosatellite MarkersMicrosatellite RepeatsMicrosatellitesMissionModelingModern ManMolecularMolecular InteractionMurineMusMutationNatureNormal CellOncogenesisOrganoidsPancreas CancerPancreatic CancerPartial MonosomyPatientsPhysiological HomeostasisPhysiopathologyProteinsPublicationsPublishingRecombinant DNA TechnologyReporterRibo-seqRibosomal RNARibosomesRoleS cerevisiaeS. cerevisiaeSaccharomyces cerevisiaeScientific PublicationStomach CancerStressTestingTherapeuticTherapeutic InterventionTranslational InhibitionTranslational RepressionUSFDAUnited States Food and Drug AdministrationXenograft ModelYeastsanti-cancer therapycancer cellcancer sub-typescancer subtypescancer therapycancer-directed therapyclinical drug development/testingdevelopmentaldrug discoverydrug mechanismendoplasmic reticulum stressexpression subtypesgastric malignancygenetically engineeredgenome mutationglioblastoma multiformeguanosinetriphosphatasehelicasein vivoindividualized cancer careindividualized oncologyinhibitorinsightintervention therapyknock-downknockdownmRNAmalignancymalignant stomach neoplasmmalignant stomach tumormembrane structuremolecular sub-typesmolecular subsetsmolecular subtypesneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoesophageal cancerpancreatic malignancypathophysiologypersonalized oncologyplan healthpolypeptideprecision cancer careprecision cancer medicineprecision oncologypreventpreventingrRNAresponseribosome footprint profilingribosome profilingsocial rolespongioblastoma multiformestomach fundus cancerstomach pylorus cancersuccesssynthetic lethal interactionsynthetic lethalitytherapeutic targettherapeutically effectivetumorigenesisxenograft transplant modelxenotransplant model
Description preview
Abstract
Synthetic lethality (SL) offers a promising approach to selectively target cancers by exploiting their genome
alterations not found in normal cells. Indeed, various inhibitors of SL drug targets are approved by the Food and
Drug Administration or in clinical trials, highlighting the potential of such a therapeutic approach. Building on…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click